TIL therapy for advanced melanoma after checkpoint inhibitors
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a treatment called tumor-infiltrating lymphocyte (TIL) therapy for people with advanced melanoma that has not responded to immune checkpoint inhibitors. TIL therapy uses your own immune cells to fight the cancer. The study aims to see if this can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You need to be able to care for yourself (ECOG performance status 0 or 1).
- You must have melanoma that cannot be removed with surgery or has spread to other parts of the body.
- You need at least one tumor that can be surgically removed, measuring at least 1.5 cm.
- You must have tried at least one treatment that includes an anti-PD-1 drug (like pembrolizumab or nivolumab) for your advanced melanoma, or you must have completed adjuvant/neoadjuvant treatment with such a drug and recovered from side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.